Individualized Conservative Therapeutic Strategies for Adenomyosis with the Aim of Preserving Fertility

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Apr 17

PMID 37064035

Authors

Lei Han

Yanni Liu

Kaixue Lao

Jianxi Jiang

Caiying Zhang

Yanlin Wang

Affiliations

Soon will be listed here.

Abstract

Adenomyosis is a diffuse or localized organic disease caused by benign invasion of endometrial glands and stroma into the myometrium. It is a common disease that seriously affects reproductive health of women in childbearing age. Due to the unknown etiology and pathophysiological mechanism, and the lack of unified diagnostic criteria and effective treatment methods, total or subtotal hysterectomy has become a radical treatment for adenomyosis, which will lead to the complete loss of fertility. With the continuous exploration of the treatment to adenomyotic patients who have infertility or fertility intentions, new drugs, surgical methods and treating concepts appears. Adopt individualized conservative therapeutic strategies for patients with different conditions, preserve the uterus as much as possible and protect the patient's fertility, which will play an important role on the follow-up assisted reproductive treatment and long-term management of adenomyosis.

References

Salmeri N, Ottolina J, Bartiromo L, Schimberni M, Dolci C, Ferrari S . 'Guess who'? An Italian multicentric study on pigmentation traits prevalence in endometriosis localizations. Eur J Obstet Gynecol Reprod Biol. 2022; 274:5-12. DOI: 10.1016/j.ejogrb.2022.05.001. View

Dasrilsyah R, Shan L, Beng Kwang N, Shafiee M, Omar M . Spontaneous conception following GnRHa and progestogen therapy in adenomyosis. Horm Mol Biol Clin Investig. 2016; 27(2):77-9. DOI: 10.1515/hmbci-2015-0061. View

Cope A, Ainsworth A, Stewart E . Current and Future Medical Therapies for Adenomyosis. Semin Reprod Med. 2020; 38(2-03):151-156. DOI: 10.1055/s-0040-1719016. View

Khan K, Fujishita A, Mori T . Pathogenesis of Human Adenomyosis: Current Understanding and Its Association with Infertility. J Clin Med. 2022; 11(14). PMC: 9316454. DOI: 10.3390/jcm11144057. View

Agostinho L, Cruz R, Osorio F, Alves J, Setubal A, Guerra A . MRI for adenomyosis: a pictorial review. Insights Imaging. 2017; 8(6):549-556. PMC: 5707223. DOI: 10.1007/s13244-017-0576-z. View

Osada H, Silber S, Kakinuma T, Nagaishi M, Kato K, Kato O . Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosis. Reprod Biomed Online. 2010; 22(1):94-9. DOI: 10.1016/j.rbmo.2010.09.014. View

Qin Z, Dong Z, Tang H, Zhang S, Wang H, Bao M . Application of modified subtotal resection of adenomyosis combined with LNG-IUS and GnRH-a sequential therapy in severe adenomyosis: A case series. Front Surg. 2022; 9:914725. PMC: 9434309. DOI: 10.3389/fsurg.2022.914725. View

Peng Y, Dai Y, Yu G, Yang X, Wen C, Jin P . Clinical evaluation of HIFU combined with GnRH-a and LNG-IUS for adenomyosis patients who failed to respond to drug therapies: two-year follow-up results. Int J Hyperthermia. 2021; 38(1):1271-1275. DOI: 10.1080/02656736.2021.1967467. View

Vannuccini S, Luisi S, Tosti C, Sorbi F, Petraglia F . Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018; 109(3):398-405. DOI: 10.1016/j.fertnstert.2018.01.013. View

10.

Rasmussen C, Hansen E, Dahl S, Ernst E, Dueholm M . The effect of transcervical endometrial resection on clinical symptoms related to intrinsic adenomyosis and junctional zone changes. Eur J Obstet Gynecol Reprod Biol X. 2019; 3:100029. PMC: 6687372. DOI: 10.1016/j.eurox.2019.100029. View

11.

Benetti-Pinto C, de Mira T, Yela D, Teatin-Juliato C, Brito L . Pharmacological Treatment for Symptomatic Adenomyosis: A Systematic Review. Rev Bras Ginecol Obstet. 2019; 41(9):564-574. DOI: 10.1055/s-0039-1695737. View

12.

Wang J, Zhai T, Sun X, Du X, Zhang X, Shi X . Efficacy and safety of acupuncture for adenomyosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(49):e28080. PMC: 8663803. DOI: 10.1097/MD.0000000000028080. View

13.

Nadarajah R, Rajesh H, Wong K, Faisal F, Yu S . Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singapore Med J. 2016; 58(6):294-297. PMC: 5474524. DOI: 10.11622/smedj.2016080. View

14.

Sun S, Zhang H, Zhong P, Xu Z . The Effect of Letrozole Combined with Dydrogesterone for Endometriosis in China: A Meta-Analysis. Biomed Res Int. 2021; 2021:9946060. PMC: 8660186. DOI: 10.1155/2021/9946060. View

15.

Prathoomthong S, Tingthanatikul Y, Lertvikool S, Rodratn N, Waiyaput W, Dittharot K . The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril. 2017; 11(4):279-286. PMC: 5641459. DOI: 10.22074/ijfs.2018.5137. View

16.

Wu J, Huang Y, Chen L, Hu J, Zou Y . Treatment of Adenomyosis with Subcutaneous Etonogestrel Implants: A Clinical Observational Study in 17 Patients. Med Sci Monit. 2018; 24:6085-6092. PMC: 6130172. DOI: 10.12659/MSM.908979. View

17.

Osada H . Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril. 2018; 109(3):406-417. DOI: 10.1016/j.fertnstert.2018.01.032. View

18.

Schindler A . Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas. 2009; 65 Suppl 1:S3-11. DOI: 10.1016/j.maturitas.2009.10.011. View

19.

Murji A, Biberoglu K, Leng J, Mueller M, Romer T, Vignali M . Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020; 36(5):895-907. DOI: 10.1080/03007995.2020.1744120. View

20.

Lee K, Kim J, Lee M, Ko Y, Yang J, Kang B . Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis. Arch Gynecol Obstet. 2016; 294(3):561-6. DOI: 10.1007/s00404-016-4105-y. View